OnCo
technologiesTechnologyPreclinical

CAR-T against stroma: fibroblasts and myeloid cells

Instead of attacking the cancer cell, engineering T cells to strip away the scaffolding and the suppressive immune cells that protect it.

FAP-directed CAR-T depletes cancer-associated fibroblasts and, in mouse models, opens desmoplastic tumours to chemotherapy and immunity; a small Swiss study delivered FAP CAR-T into the pleural cavity in mesothelioma. Myeloid-directed approaches target CSF1R, TREM2, or CD163 populations. The recurring problem is that FAP and myeloid markers are not tumour-specific: FAP is expressed in bone-marrow stroma and healing tissue, and murine FAP CAR-T caused cachexia and marrow toxicity in early studies.

Generic schematic · not to scale · placeholder for the cell therapy front
T cell + CAR transgene · CAR binds antigen (no MHC needed) · Tumour cell

How it works

A CAR recognises a stromal antigen rather than a tumour antigen; killing the supporting cells collapses the niche the tumour depends on.

Strengths
  • Stroma is genetically stable, so it cannot mutate away
  • One construct could serve many cancers
  • Combines with drugs that stroma currently blocks
Limitations
  • On-target off-tumour toxicity: marrow, wound healing, cachexia
  • No registrational programme
  • Depleting stroma accelerated disease in some pancreatic models

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this technology: (TITLE:"CAR-T against stroma: fibroblasts and myeloid cells" OR ABSTRACT:"CAR-T against stroma: fibroblasts and myeloid cells") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CAR-T against stroma: fibroblasts and myeloid cells, not a curated reading list.

Connected

10top

Pages like this

not linked directly; found by shared links